Sonnemed Patent Filing

(WO/2009/129321) COMPOUNDS AND METHODS FOR ACTIVATED THERAPY

Pub. No.:		WO/2009/129321

Publication Date: 22.10.2009
International Application No.: PCT/US2009/040688
International Filing Date: 15.04.2009

• Description
• Claims
• National Phase
• Notices
• Document

Applicants:
SONNEMED LLC [US/US]; 10 Mt. Vernon Street, #208 Winchester, MA 01890 (US) (All Except US).
LEWIS, Thomas [US/US]; (US) (US Only).
SZULWACH, Ann, M. [US/US]; (US) (US Only).

Inventors:
BURKE, Donald; .
LEWIS, Thomas; (US).

Title:
COMPOUNDS AND METHODS FOR ACTIVATED THERAPY

Abstract:
Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using sonodynamic and/or photodynamic methods. In particular, photosensitizer and/or sonosensitizer compounds that collect in hyperproliferative tissue are provided.

Description
[Snips]
The compounds of the invention are useful as sonosensitizers, photosensitizers and/or as dual acting sensitizers as therapeutic and diagnostic agents, for example for treatment of several cancer types such as, but not limited to, melanoma, prostate, brain, colon, ovarian, breast, skin, lung, esophagus and bladder cancers and other hormone-sensitive tumors, as well as for treatment of age-related macular degeneration, and for killing cells, viruses, fungi and bacteria in samples and living tissues as well known in the art of PDT and other sonosensitizer applications.
....

The invention further relates to a method of sonodynamic therapy, which comprises administering to an individual in need an effective amount of a compound of the invention, followed by local ultrasound. The compounds of the invention are also useful for photo- and sonodestruction of normal or malignant animal cells, as desired, as well as of microorganisms in culture, enabling selective photo- and sonodestruction of certain types of cells in culture or infective agents. Thus, the invention further provides the use of the compounds of the invention for in vivo, ex-vivo or in vitro killing of cells or infectious agents such as bacteria, viruses, parasites and fungi in a biological product, e.g. blood, which comprises treating the infected sample with the compound of the invention followed by ultrasound of the sample. Examples of such diseases or conditions include acne, Aids, viral hepatitis, diabetic retinopathy, infection with sars virus, coronary artery stenosis, carotid artery stenosis, intermittent claudication, or Asian (chicken) flu virus, or infections caused by intracellular infectious agents such as Clamidia, tox, ricetzia, rocky mountain spotted fever, q-fever, and others.

Source

Posted by donpatent at 2:24 PM

See also United States Patent Application 20090275548

XIAOHUAI WANG - acoustodynamic therapy

Application of porphyrin class in preparation of sound motivation therapy medicine and sound motivation therapy

Bibliographic data

Description

Claims

Mosaics

Original document

INPADOC legal status

	Publication number: CN101156848 (A) Publication date: 2008-04-09 Inventor(s): XIAOHUAI WANG [CN]; JIANGAN SU [CN]; QING LI [CN]; GUANGLIAN ZHAO [CN]; YIFAN LUO [CN]; BO YU [CN] Applicant(s): BO YU [CN] Classification: - international: A61K31/409; A61P35/00; A61K31/409; A61P35/00 - European: Application number: CN20071164244 20070930 Priority number(s): CN20071164244 20070930 View INPADOC patent family View list of citing documents Report a data error here Abstract of CN 101156848 (A) The invention provides the application of porphyrin chemical compound which is in one of the right formulas in preparing a drug of acoustodynamic therapy and the acoustodynamic therapy. The acoustodynamic therapy includes the steps that the porphyrin chemical compound is applied to a patient, and then acoustic wave acts on the patient, wherein, the meaning of each symbol is as stated in the instruction. Data supplied from the esp@cenet database — Worldwide

Source

In this Chinese patent - 'chlorlin' is mentioned and this is Wikipedia's description for 'chlorin' - no 2nd "l" (which may be correct, at least it involves PDT):

Chlorin:
From Wikipedia, the free encyclopedia

Jump to: navigation, search

For the chemical element in the halogen group see chlorine.

Chlorin
Identifiers
PubChem	65106
SMILES	[show] C1CC2=NC1=CC3=CC=C(N3)C=C4C=CC(=N4)C=C5C=CC(=C2)N5
Properties
Molecular formula	C20H16N4
Molar mass	312.36784
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox references

In organic chemistry, a chlorin is a large heterocyclic aromatic ring consisting, at the core, of three pyrroles and one pyrroline coupled through four methine linkages. Unlike a porphyrin, a chlorin is therefore largely aromatic but not aromatic through the entire circumference of the ring.

Magnesium-containing chlorins are called chlorophylls, and are the central photosensitive pigment in chloroplasts. A related compound, with two reduced pyrroles, is called a bacteriochlorin.

Because of their photosensitivity, chlorins are in active use as photosensitizing agents in experimental Photodynamic Therapy.

See also: Sonodynamic therapy (mentions SonneMed)

SonneMed - Sonodynamic Therapy

The Tumoricidal Effect of Sonodynamic Therapy (SDT) on S-180

Integrative Cancer Therapies, Vol. 7, No. 2, 96-102 (2008)
DOI: 10.1177/1534735408319065

Sarcoma in Mice
Xiaohuai Wang, MD

Department of Oncology, Liu Hua Qiao Hospital, Guangzhou, P. R. China, tlewis@sonnemed.com

Thomas J. Lewis, PhD

SonneMed LLC, Boston, Massachusetts

Doug Mitchell, PhD

There are increasing data showing that sonodynamic therapy (SDT), which refers to a synergistic effect of drugs and ultrasound, is a promising new modality for cancer treatment. However, few clinical data on SDT have been published. One reason is the lack of suitable drugs for clinical SDT use. Recently a new sonosensitizing agent has been developed by SonneMed, LLC, referred to as SF1. In this study the effect of SDT with SF1 on S-180 sarcoma in mice was examined. The tumor bearing mice were allocated to the following groups: (1) sham-treatment (control, C); (2) ultrasound treatment (only ultrasound treatment, 1.2 mW/cm2 , without SF1, U); (3) SF1 treatment (SF1 20 mg/kg intraperitoneal [ip] without ultrasound treatment, S); and (4) SF1 + ultrasound treatment (SU). Following treatment, tumor volume was monitored. Tumor growth inhibition was seen only in group SU, and with increasing ultrasound intensity, the inhibitory effect was enhanced. Tumor growth inhibition was also visible even when covered by a barrier of bone. Pathological slices showed coagulated necrosis or metamorphic tissue with inflammatory reaction in the tumor taken from 2 to 36 hours after SDT. These data revealed that SDT with SF1 did inhibit growth of mouse S-180 sarcoma and the inhibitory effect was sound intensity dependent. SDT also induced some inflammation while it destroyed the tumor, indicative of a "vaccine" effect. SF1 shows great promise for clinical use in the future.

Key Words: photodynamic therapy • sonodynamic therapy • cancer • cancer therapy • tumor necrosis • tumoricidal • poryphrins • SonneMed • mouse S-180 sarcoma • anticancer

Source